Acquired von Willebrand Syndrome: from Pathophysiology to Management

Agnès Veyradier; Charles S. P. Jenkins; Edith Fressinaud; Dominique Meyer

doi:10.1055/s-0037-1613993

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2000; 84(02): 175-182
DOI: 10.1055/s-0037-1613993

Review Article

Schattauer GmbH

Acquired von Willebrand Syndrome: from Pathophysiology to Management

Agnès Veyradier

¹From INSERM U143, Hôpital de Bicêtre, Le Kremlin Bicêtre and Service d’Hématologie biologique, Hôpital Antoine Béclère, Clamart, France

,

Charles S. P. Jenkins

²American Red Cross, Chapel Hill, NC, USA

,

Edith Fressinaud

³Laboratoire d’Hématologie, CHU Hôtel Dieu, Nantes, France

,

Dominique Meyer

¹From INSERM U143, Hôpital de Bicêtre, Le Kremlin Bicêtre and Service d’Hématologie biologique, Hôpital Antoine Béclère, Clamart, France

› Author Affiliations

Abstract

Summary

Acquired von Willebrand syndrome (AvWS) is a rare and probably underestimated bleeding disorder which mimicks most of the clinical symptoms and laboratory features of hereditary von Willebrand disease (vWD) in patients devoid of both personal and familial history of bleeding diathesis (1). AvWS and congenital vWD both result from a defect in von Willebrand factor (vWF), a large multimeric glycoprotein present in megakaryocytes, platelets, endothelial cells, subendothelium and mainly in plasma (2). vWF is essential to platelet adhesion and aggregation at the site of vascular injury by acting as a bridge between platelet receptors and the collagen of the subendothelium as well as between platelets themselves. vWF binds to both platelet receptors glycoprotein (GP) Ib and GP IIb/IIIa and also to coagulation factor VIII (F.VIII) acting as a stabilizing carrier protein in plasma. The revised classification of hereditary vWD (3) includes three major types: type 1 and type 3 are respectively related to a partial or a total quantitative defect while type 2 (variants including several subtypes) results from a qualitative defect of vWF. Although vWD is well known to be the most common inherited bleeding disorder with a worldwide prevalence of 1 to 2% (1), more than 200 cases of AvWS have been reported since it was described in 1968 (4). It is likely, however, that this number is underestimated since isolated case-reports of AvWS tend to be less published and its diagnosis remains difficult. AvWS is most commonly found together with a variety of concurrent diseases which are mainly clonal hematoproliferative, neoplasia and autoimmune disorders (5-7). The pathophysiological basis of AvWS as well as its response to treatment depend clearly on the associated underlying disease. In this paper, we summarized all the situations where an AvWS may be observed as a function of the anamnestic and clinical data, the pathogenic mechanisms and the laboratory features. Moreover, we propose a therapeutic flow chart based on both data from the literature and personal experience.

Keywords

von Willebrand factor (vWF) - hematoproliferative diseases - inhibitor to vWF

Full Text

References

References
1 Nichols WC, Ginsburg D. von Willebrand disease. Medecine 1997; 76: 1-20.
2 Meyer D, Girma JP. von Willebrand factor: structure and function. Thromb Haemost 1993; 70: 99-104.
3 Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71: 520-5.
4 Simone JV, Cornet JA, Abilgoard CF. Acquired von Willebrand’s syndrome in systemic lupus erythematosus. Blood 1968; 31: 806-12.
5 Tefferi A, Nichols WL. Acquired von Willebrand disease: concise review of occurrence, diagnosis, pathogenesis, and treatment. Am J Med 1997; 103: 536-40.
6 Rinder MR, Richard RE, Rinder HM. Acquired von Willebrand’s disease: a concise review. Am J Hematol 1997; 54: 139-45.
7 van Genderen PJ, Michiels JJ. Acquired von Willebrand’s disease. Baillieres Clin Haematol 1998; 11: 319-30.
8 Mohri H, Motomura S, Kanamori H, Matsuzaki M, Watanabe S, Maruta A, Kodama F, Okubo T. Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood 1998; 91: 3623-9.
9 Mannucci PM. Platelet von Willebrand factor in inherited and acquired bleeding disorders. Proc Natl Acad Sci USA 1995; 92: 2428-32.
10 Jakway JL. Acquired von Willebrand disease in malignancy. Sem Thromb Haemost 1992; 18: 434-9.
11 Glaspy JA. Disturbances in hemostasis in patients with B-cell malignancies. Sem Thromb Haemost 1992; 18: 440-8.
12 Budde U, Schaefer G, Mueller N, Egli H, Dent J, Ruggeri Z, Zimmerman T. Acquired von Willebrand’s disease in the myeloproliferative syndrome. Blood 1984; 64: 981-5.
13 van Genderen PJ, Leenknegt H, Michiels JJ, Budde U. Acquired von Willebrand disease in myeloproliferative disorders. Leuk Lymphoma 1996; 22 (Suppl. 01) 79-82.
14 Handin RI, Martin V, Moloney WC. Antibody-induced von Willebrand’s disease: a newly defined inhibitor syndrome. Blood 1976; 48: 393-405.
15 Gan TE, Sawers RJ, Koutts J. Pathogenesis of antibody-induced acquired von Willebrand syndrome. Am J Hematol 1980; 09: 363-71.
16 Mannucci PM, Lombardi R, Bader R, Horellou MH, Einazzi G, Cesana C, Conrad J, Samama M. Studies of the pathophysiology of acquired von Willebrand’s disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies. Blood 1984; 64: 614-21.
17 Fricke WA, Brinkhous KM, Garris JB, Roberts HR. Comparison of inhibitory and binding characteristics of an antibody causing acquired von Willebrand syndrome: an assay for von Willebrand factor binding by antibody. Blood 1985; 66: 562-9.
18 Goudemand J, Samor B, Caron C, Jude B, Gosset D, Mazurier C. Acquired type II von Willebrand’s disease: demonstration of a complexed inhibitor of the von Willebrand factor-platelet interaction and response to treatment. Br J Haematol 1988; 68: 227-33.
19 Stewart AK, Glynn MFX. Acquired von Willebrand disease associated with free lambda light chain monoclonal gammopathy, normal bleeding time and response to prednisone. Postgrad Med J 1990; 66: 560-4.
20 Scrobohaci ML, Daniel MT, Levy Y, Marolleau JP, Brouet JC. Expression of GpIb on plasma cells in a patient with monoclonal IgG and acquired von Willebrand disease. Br J Haematol 1993; 84: 471-5.
21 van Genderen PJJ, Vink T, Michelo JJ, van’t Veer MB, Sixma JJ, van Vliet HDM. Acquired von Willebrand disease caused by an antibody selectively inhibiting the binding of von Willebrand factor to collagen. Blood 1994; 84: 3780-4.
22 Borill EG, Erschler WB, Golden GA, Tindle BH, Edson JR. A human myeloma produced monoclonal protein directed against the active subpopulation of von Willebrand factor. Am J Pathol 1986; 85: 115-23.
23 Takahashi H, Nagayama R, Tanake Y, Satoh K, Hanano M, Mito M, Shibata A. DDAVP in acquired von Willebrand syndrome associated with multiple myeloma. Am J Hematol 1986; 22: 421-9.
24 Richard C, Cuadrado MA, Prieto M, Battle J, Lopez-Fernandez MF, Rodriguez MLSalazo, Bello C, Recio M, Santoro T, Gomez-Cabares MT, Zubizarreta A. Acquired von Willebrand’s disease in multiple myeloma secondary to adsorption of von Willebrand factor by plasma cells. Am J Hematol 1990; 35: 114-7.
25 Glaspy JA. Hemostatic abnormalities in multiple myeloma and related disorders. Hematol Oncol Clin North Am 1992; 06: 1301-14.
26 Mohri H, Noguchi T, Kodama F, Itoh A, Ohkubo T. Acquired von Willebrand disease due to inhibitor of human myeloma protein specific for von Willebrand factor. Am J Clin Pathol 1987; 87: 663-8.
27 Mohri H, Tanabe J, Ohtsuka M, Yoshida M, Motomura S, Nishida S, Fujimura Y, Okudo T. Acquired von Willebrand disease associated with a multiple myeloma; characterization of an inhibitor to von Willebrand factor. Blood Coag Fibrin 1995; 06: 561-6.
28 Mohri H, Hisanaga S, Mishima A, Fujimoto S, Uezono S, Okudo T. Autoantibody inhibits binding of von Willebrand factor to glycoprotein Ib and collagen in multiple myeloma: recognition sites present on the A1 loop and A3 domains of von Willebrand factor. Blood Coag Fibrin 1998; 09: 91-7.
29 Brody JI, Hardor ME, Resman RE. A hemorrhagic syndrome in Waldenström’s macroglobulinemia secondary to immuno-adsorption of factor VIII. N Engl J Med 1979; 300: 408-10.
30 Mazurier C, Parquet-Germez A, Descamps J, Bauters F, Goudemand M. Acquired von Willebrand’s syndrome in the course of Waldenström’s disease. Thromb Haemost 1980; 44: 115-8.
31 Wautier JL, Levy-Toledano ST, Caen JP. Acquired von Willebrand’s syndrome and thrombopathy in a patient with chronic lymphocytic leukaemia. Scand J Haematol 1976; 16: 128-39.
32 Roussi JH, Houbouyan LL, Alterescu R, Franc B, Goguel AF. Acquired von Willebrand’s syndrome associated with hairy cell leukaemia. Br J Haematol 1980; 46: 503-6.
33 Rao KPP, Kizer J, Jones TJ, Anunciado A, Pepkowitz S, Lazarchi J. Acquired von Willebrand’s syndrome associated with an extra nodal pulmonary lymphoma. Arch Pathol Lab Med 1988; 112: 47-50.
34 Tran-Thang C, Mannucci PM, Schreider PH, Federici A, Bachman F. Profound alterations of the multimeric structure of von Willebrand’s factor in a patient with malignant lymphoma. Br J Haematol 1985; 61: 307-14.
35 Tefferi A, Hanson CA, Kurtin PJ, Katzmann JA, Dalton RJ, Nichols WL. Acquired von Willebrand disease due to aberrant expression of platelet glycoprotein Ib by marginal zone lymphoma cells. Br J Haematol 1997; 96: 850-853.
36 Kaywin P, McDonough M, Inact PA, Shattil SJ. Platelet function in essential thrombocythemia. N Engl J Med 1978; 299: 505-9.
37 Raman BKS, Sawdyk M, Saced SM. Essential thrombocythemia with acquired von Willebrand’s disease. Am J Clin Pathol 1987; 88: 102-6.
38 Sato K. Plasma von Willebrand factor abnormalities in patients with essential thrombocythemia. Keio J Med 1988; 37: 54-71.
39 Carter C, Boughton BJ. Acquired von Willebrand’s disease in myeloproliferative syndrome: spontaneous remission during pregnancy. Thromb Haemost 1992; 67: 387-8.
40 van Genderen PJJ, Michiels JJ. Primary thrombocythemia: diagnosis, clinical manifestations and management. Ann Hematol 1993; 67: 57-62.
41 Budde U, Scharf RE, Franke P, Hartmann-Budde K, Dent J, Ruggeri ZM. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 1993; 82: 1749-57.
42 van Genderen PJJ, Michiels JJ, van der Poel-van de Luytgaarde SC, van Vliet HH. Acquired von Willebrand disease as a cause of reccurent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count. Ann Hematol 1994; 69: 81-84.
43 Castaman G, Lattuada A, Ruggeri M, Tosetto A, Mannucci PM, Rodeghiero F. Platelet von Willebrand factor abnormalities in myeloproliferative syndromes. Am J Hematol 1995; 49: 289-93.
44 Budde U, van Genderen PJJ. Acquired von Willebrand disease in patients with high platelet counts. Sem Thromb Haemost 1997; 23: 425-31.
45 van Genderen PJJ, Leenknegt H, Michiels JJ. The paradox of bleeding and thrombosis in thrombocythemia: is von Willebrand factor the link?. Sem Thromb Haemost 1997; 23: 385-9.
46 van Genderen PJJ, Prins FJ, Lucas IS, van de Moessdijk D, van Vliet HH, van Strik R, Michiels JJ. Decreased half life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count. Br J Haematol 1997; 99: 832-6.
47 van Genderen van Vliet HH, Prins FJ, van de Moesdijk D, van Strik R, Zijlstra FJ, Budde U, Michiels JJ. Excessive prolongation of the bleeding time by aspirin in essential thrombocythemia is related to a decrease of large von Willebrand factor multimers in plasma. Ann Haematol 1997; 75: 215-20.
48 Mohri H. Acquired von Willebrand’s disease in patients with polycythemia rubra vera. Am J Hematol 1987; 26: 135-46.
49 Duran-Saurez JR, Pico M, Zuazu J. Acquired von Willebrand’s disease caused by a chronic granulocytic leukaemia. Br J Haematol 1981; 48: 173-4.
50 Mohri H. Acquired von Willebrand’s disease and storage pool disease in chronic myelocytic leukemia. Am J Hematol 1986; 22: 391-401.
51 Mohri H, Tanabe J, Yamazaki E, Yoshida M, Harano H, Matsuzaki M, Motomura S, Okubo T. Acquired type 2A von Willebrand disease in chronic myelocytic leukemia. Hematopathol Mol Hematol 1996; 10: 123-33.
52 Noronha PA, Houby MA, Maurer HS. Acquired von Willebrand disease in a patient with Wilm’s tumor. J Pediatr 1979; 95: 997-9.
53 Scott JP, Montgomery RR, Tubergen DG, Hays T. Acquired von Willebrand’s disease in association with Wilm’s tumor: regression after treatment. Blood 1987; 58: 247-57.
54 Bracey AW, Wu AHB, Aceves J. Platelet dysfunction associated with Wilms tumor and hyaluronic acid. Am J Hematol 1987; 24: 247-57.
55 Coppes MJ, Zandroort SWH, Sparling CR, Poon AO, Weitzman S, Blanchette VS. Acquired von Willebrand’s disease in Wilm’s tumor patient. J Clin Oncol 1992; 10: 422-7.
56 de Graab JH, Tamminga RYJ, Kamps WA. Paraneoplasic manifestations in children. Europ J Pediat 1994; 153: 784-91.
57 Jonge ABPaerink-Stockschläder, Dekker I, Risseeulus-Appel IM, Hählen K. Acquired von Willebrand’s disease in children with Wilms tumor. Med Ped Oncol 1996; 26: 238-43.
58 Sampson BM, Greaves M, Malia RG, Preston FE. Acquired von Willebrand’s disease: demonstration of a circulating inhibitor to the F.VIII complex in four cases. Br J Haematol 1983; 54: 233-44.
59 Facon T, Caron C, Courtin P, Wurte A, Deghaye M, Bauters F, Mazurier C, Goudemand J. Acquired type II von Willebrand disease associated with adrenal cortical carcinoma. Brit J Haematol 1992; 80: 488-94.
60 Nowak-Göttl U, Kehrel B, Budde U, Hoffman C, Winkelman W, Jürgens H. Acquired von Willebrand’s disease in malignant peripheral neuroectodermal tumor. Med Ped Oncol 1995; 25: 117-8.
61 Ingram GI, Kingston PJ, Leslie J, Bowie EJ. Four cases of acquired von Willebrand’s syndrome. Br J Haematol 1971; 21: 189-99.
62 Soff GA, Green D. Autoantibody to von Willebrand factor in systemic lupus erythematosus. J Lab Clin Med 1992; 121: 424-30.
63 Dalton RG, Savidge GF, Matthews KB, Dewar S, Kernoff PBA, Greaves M, Preston FE. Hypothyroidism as a cause of acquired von Willebrand’s disease. Lancet 1987; 01: 1007.
64 MacCallum PK, Rodgers M, Taberner DA. Hypothyroidism and von Willebrand’s disease. Lancet 1987; 01: 1314.
65 Smith SR, Auger MJ. Hypothyroidism and von Willebrand’s disease. Lancet 1987; 01: 1314.
66 Thorton JG, Parpia LA, Minford AMB. Hypothyroidism and von Willebrand’s disease. Lancet 1987; 01: 1314-5.
67 Palareti G, Biagi G, Legrani C, Bianchi D, Serra D, Sairni R, Coccheri S. Association of reduced factor VIII with impaired platelet reactivity to adrenalin and collagen after total thyroidectomy. Thromb Haemost 1989; 62: 1053-6.
68 Blessing NE, Hambley H, McDonald GA. Acquired von Willebrand’s disease and hypothyroidism: report of a case presenting menorrhagia. Postgrad Med J 1990; 66: 474-6.
69 Coccia MR, Barnes HV. Hypothyroidism and acquired von Willebrand’s disease. J Adolesc Health 1991; 12: 152-4.
70 Levesque H, Borg JY, Cailleux N, Vasse M, Daliphard S, Gancel A, Monconduit M, Courtois H. Acquired von Willebrand’s syndrome associated with decrease of plasminogen activator and its inhibitor during hypothyroidism. Eur J Med 1993; 02: 287-8.
71 Bruggers CS, McElligott K, Rallison ML. Acquired von Willebrand in twins with autoimmune hypothyroidism: response to desmopressin and L-thyroxine therapy. J Pediatr 1994; 125: 911-3.
72 Tjan-Heijen VC, Harthoom-Lasthuizen KJ, Kurstjens RM, Koolen MI. A patient with postpartum primary hypothyroidism and acquired von Willebrand’s disease. Neth J Med 1994; 44: 91-4.
73 Attivissimo LA, Lichtman SM, Klein I. Acquired von Willebrand syndrome causing a hemorrhagic diathesis in a patient with hypothyroidism. Thyroid 1995; 05: 399-401.
74 Aylesworht CA, Smallridge RC, Rick ME, Alving BM. Acquired von Willebrand’s disease: a rare manifestation of postpartum thyroitidis. Am J Hematol 1995; 50: 217-9.
75 Leone G, Pola P, Guerrera G, Bizzi B. Acquired von Willebrand’s syndrome during collagen disorder. Haematologica 1974; 59: 212-20.
76 Mannucci PM, Lombardi R, Lattuada A, Perticucci E, Valsecchi R, Rumuzzi G. Supranormal von Willebrand factor multimers in scleroderma. Blood 1987; 73: 1586-91.
77 Yoshida H, Arai K, Wakashin M. Development of acquired von Willebrand’s disease after mixed connective tissue disease. Am J Med 1988; 85: 445-6.
78 Lazarchick J, Green C. Acquired von Willebrand disease following bone marrow transplantation. Ann Clin Lab Sci 1994; 24: 211-5.
79 Gralnick HR, McKeown LP, Williams SB, Strafer BC, Pierce L. Plasma and platelet von Willebrand factor defects in uremia. Am J Med 1988; 85: 806-10.
80 Rodeghiero F, Castaman G, Lombardi R, Mannucci PM. von Willebrand factor abnormalities in two patients with uraemia. Lancet 1988; 01: 1016-7.
81 Castaman GC, Rodeghiero F, Lattuada A, La Greca CZ, Mannucci PM. Multimeric pattern of plasma and platelet von Willebrand factor is normal in uremic patients. Am J Hematol 1993; 44: 266-9.
82 Gill JC, Wilson AD, Endres-Brooks J, Montgomery RR. Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects. Blood 1986; 67: 758-61.
83 Froom P, Margulis T, Grenadier E, Palant A, David M, Aghai E. von Willebrand factor and mitral valve prolapse. Thromb Haemost 1988; 60: 230-1.
84 Warkentin TE, Moore JC, Morgan DG. Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand’s disease the link?. Lancet 1992; 340: 35-7.
85 O’Brien JR, Etherington MD. Heart valve stenosis and von Willebrand’s factor multimers. Lancet 1992; 340: 616.
86 Anderson RP, Mc KGrawth, Street A. Reversal of aortic stenosis, bleeding gastrointestinal angiodysplasia, and von Willebrand syndrome by aortic valve remplacement. Lancet 1996; 347: 689-90.
87 Wautier JL, Caen JP, Rymer R. Angiodysplasia in acquired von Willebrand disease. Lancet 1976; 02: 973.
88 Rosborough TK, Swaim WR. Acquired von Willebrand’s disease, platelet-release defect and angiodysplasia. Am J Med 1978; 65: 96-100.
89 Mc KMGrawth, Johnson CA, Stuart JJ. Acquired von Willebrand disease associated with an inhibitor to factor VIII antigen and gastrointestinal telangiectasia. Am J Med 1979; 67: 693-6.
90 Cass AJ, Bliss BP, Bolton RP, Cooper BT. Gastrointestinal bleeding, angiodysplasia of the colon and acquired von Willebrand’s disease. Br J Surg 1980; 67: 639-41.
91 Woodlock TJ, Francis CW, Rowe JM, Brown MJ, Marder VJ. Prolonged remission after life-threatening gastrointestinal hemorrhage from coexistent angiodysplasia and acquired bleeding diathesis. Am J Hematol 1988; 27: 125-31.
92 Fressinaud E, Meyer D. International survey of patients with von Willebrand disease and angiodysplasia. Thromb Haemost 1993; 70: 546.
93 Inbal A, Bank I, Zivelin A, Varon D, Dardik R, Shapiro R, Rosenthal E, Shenkman B. Acquired von Willebrand disease in a patient with angiodysplasia resulting from immune-mediated clearance of von Willebrand factor. Br J Haematol 1997; 96: 179-82.
94 Kinoshita S, Yoshioka K, Kasahara M, Takamiya O. Acquired von Willebrand disease after Epstein-Barr virus infection. J Pediatrics 1991; 119: 595-8.
95 Richard C, Sedano MC, Cuadrado MA, Recio M, Hermosa V, Zubizarreta A. Acquired von Willebrand’s syndrome associated with hydatid disease of the spleen. Disappearance after splenectomy. Thromb Haemost 1984; 52: 90-3.
96 Clough V, MacFarlane IA, O’Connor J, Woud JK. Acquired von Willebrand’s syndrome and Ehlers-Danlos syndrome presenting with gastrointestinal bleeding. Scand J Haematol 1979; 22: 305-10.
97 Parker RI, McKeown LP, Grallin SI, Gralnick HR. Absence of the largest platelet von Willebrand multimers in a patient with lactoferrin deficiency and a bleeding tendency. Thromb Haemost 1992; 67: 320-4.
98 Benson PJ, Peterson LC, Hasegaura DK, Smith CM. Abnormality of von Willebrand factor in patients with hemoglobin E-β thalassemia. Am J Clin Pathol 1990; 93: 395-9.
99 Conrad ME, LaTour LF. Acquired von Willebrand’s disease, IgE polyclonal gammopathy and griseofulvin therapy. Am J Hematol 1992; 41: 143.
100 Castaman G, Rodeghiero F. Acquired transitory von Willebrand syndrome with ciprofloxacin. Lancet 1994; 343: 492.
101 Castaman G, Lattuada A, Mannucci PM, Rodeghiero F. Characterization of two cases of acquired transitory von Willebrand syndrome with ciprofloxacin. Am J Hematol 1995; 49: 83-6.
102 Kreuz W, Linde R, Funk M, Meyer-Schrod R, Föll E, Nowak-Göttl U, Jacobi G, Vigh ZS, Scharrer I. Induction of von Willebrand disease type I by valproic acid. Lancet 1990; 335: 1350-1.
103 Strauss RG, Stump DC, Henriksen RA. Hydroxyethyl starch accentuates von Willebrand’’s disease. Transfusion 1985; 25: 235-7.
104 Sanfelippo MJ, Subernola PD, Geimer NF. Development of a von Willebrand-like syndrome after use of hydroxyl starch. Am J Clin Pathol 1987; 88: 653-5.
105 Dalrymphyle-Hay M, Aitchison R, Collins R, Sekhar M, Calvin B. Hydroxy-ethyl starch induced acquired von Willebrand’s disease. Clin Lab Haematol 1992; 14: 209-11.
106 Stableforth P, Tamognini GL, Dormandy KM. Acquired von Willebrand syndrome with inhibitors both to factor VIII clotting activity and ristocetin-induced platelet aggregation. Br J Haematol 1976; 33: 565-73.
107 Gouault-Heilmann M, Dumont MD, Intrator L, Chenal C, Lejonc JL. Acquired von Willebrand’s syndrome with IgM inhibitor against von Willebrand factor. J Clin Path 1979; 32: 1030-5.
108 Stewart MW, Etches WS, Shaw ARE, Gordon PA. vWF inhibitor detection by competitive ELISA. J Immunol Methods 1997; 200: 113-9.
109 Budde U, Dent JA, Barkowitz SD, Ruggeri ZM, Zimmerman TS. Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. Blood 1986; 68: 1213-7.
110 Tatewaki W, Takahashi H, Takakuwa E, Wada K, Shibata A. Plasma von Willebrand factor proteolysis in patients with chronic myeloproliferative disorders: no possibility of ex vivo degradation by calcium-dependent proteases. Thromb Res 1989; 56: 191-9.
111 Federici AB, D’Amico EA. The role of von Willebrand factor in the hemostatic defect of acute promyelocytic leukemia. Leuk Lymphoma 1998; 31: 491-9.
112 Eikenboom JCJ, van der Meer FJM, Briet E. Acquired von Willebrand’s disease due to excessive fibrinolysis. Br J Haematol 1992; 81: 618-20.
113 Heyde EC. Gastrointestinal bleeding in aortic stenosis. N Engl J Med 1958; 259: 196.
114 Greenstein RJ, McGlhinney AJ, Reuben D, Greenstein AJ. Colonic vascular ectasias and aortic stenosis: coincidence or causal relationship?. Am J Surg 1986; 151: 347-51.
115 King RM, Pluth JR, Giuliani ER. The association of unexplained gastrointestinal bleeding with calcific aortic stenosis. Ann Thorac Surg 1987; 44: 514-6.
116 Cappell MS, Lebwohl O. Cessation of recurrent bleeding from gastrointestinal angiodysplasia after aortic valve replacement. Ann Intern Med 1986; 105: 54-7.
117 Veyradier A, Fressinaud E, Meyer D. Laboratory diagnosis of von Willebrand disease. Int J Clin Lab Res 1998; 28: 201-10.
118 Fressinaud E, Veyradier A, Truchaud F, Martin I, Boyer-Neumann C, Trossaert M, Meyer D. Screening for von Willebrand disease using a new analyzer utilizing high shear stress: a study of 60 cases. Blood 1998; 91: 1325-31.
119 De Romeuf C, Mazurier C. Comparison between von Willebrand factor (vWF) and vWF antigen II in normal individuals and patients with von Willebrand disease. Thromb Haemost 1998; 80: 37-41.
120 van Genderen PJJ, Boertjes RC, van Mourik JA. Quantitative analysis of von Willebrand factor and its propeptide in plasma in acquired von Willebrand syndrome. Thromb Haemost 1998; 80: 495-8.
121 Mohri H, Yamazaki E, Suzuki Z, Takano T, Yokoza S, Okudo T. Autoantibody selectively inhibits binding of vWF to GPIb. Recognition site is localized in the A1 loop of vWF. Thromb Haemost 1997; 77: 760-6.
122 Cattaneo M. Review of clinical experience of desmopressin in patients with congenital and acquired bleeding disorders. Eur J Anaesthesiol 1997; 14 suppl: 10-4.
123 Meyer D, Frommel D, Larrieu MJ, Zimmerman TS. Selective absence of large forms of factor VIII/von Willebrand factor in acquired von Willebrand’s syndrome. Response to transfusion. Blood 1979; 54: 600-6.
124 Jehlinger J, Rose E, Aledort LM. Successful treatment of an acquired von Willebrand factor antibody by extracorporeal immunoadsorption. N Engl J Med 1989; 320: 254-5.
125 van Genderen PJJ, Michiels JJ, Bakker JJ, van’t Veer MB. Effectiveness of high-dose intravenous gammaglobulin therapy in acquired von Willebrand’s disease. Vox Sang 1994; 87: 14-7.
126 van Genderen PJJ, Paptsonio DNM, Michiels JJ, Wielenga JJ, Stiffe J, Huikeshoven FJM. High-dose intravenous gammaglobulin therapy for acquired von Willebrand disease. Postgrad Med 1994; 70: 916-20.
127 van Genderen PJJ, Terpstra W, Michiels JJ, Kapteijn L, van Vliet HHDM. High-dose intravenous immunoglobulin delays clearance of von Willebrand factor in acquired von Willebrand disease. Thromb Haemost 1995; 73: 891-2.
128 Federici AB, Stabile F, Castaman G, Canciani MT, Mannucci PM. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood 1998; 92: 2707-11.
129 Castaman G, Tosetto A, Rodeghiero F. Effectiveness of high-dose intravenous immunoglobulin in a case of acquired von Willebrand syndrome with chronic melena not responsive to desmopressin and factor VIII concentrate. Am J Hematol 1992; 41: 132-6.
130 White LA, Chisholm M. Gastrointestinal bleeding in acquired von Willebrand’s disease: efficacy of high-dose immunoglobulin where substitution treatments failed. Br J Haematol 1993; 84: 332-4.
131 Gross S, Traulle C, Capiod JC, Roussel B, Lafon B, Hayek E, Dieval J, Delobel J. Efficacy of high-dose intravenous gammaglobulin in the management of acquired von Willebrand’s disease during orthopaedic surgery. Br J Haematol 1992; 82: 171-2.
132 Federici AB, Rand JH, Mancini V, Bucciarelli P, Mannucci PM. Diagnosis and therapy of acquired von Willebrand syndrome (AvWS): report on 211 cases of the international registry of AvWS. Blood 1998; 92 (10 suppl 1): 556a.
133 Feinstein DI, Green D, Federici AB, Goodnight SH. Diagnosis and Management of Patients with Acquired Inhibitors of Coagulation. Editorial Book of the American Society of Hematology 1999; 192-208.